ATE457979T1 - Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate - Google Patents
Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivateInfo
- Publication number
- ATE457979T1 ATE457979T1 AT06785258T AT06785258T ATE457979T1 AT E457979 T1 ATE457979 T1 AT E457979T1 AT 06785258 T AT06785258 T AT 06785258T AT 06785258 T AT06785258 T AT 06785258T AT E457979 T1 ATE457979 T1 AT E457979T1
- Authority
- AT
- Austria
- Prior art keywords
- formula
- androgen receptor
- receptor modulators
- compound
- derivatives usable
- Prior art date
Links
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 1
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69360405P | 2005-06-24 | 2005-06-24 | |
| PCT/US2006/024122 WO2007002181A2 (en) | 2005-06-24 | 2006-06-21 | Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE457979T1 true ATE457979T1 (de) | 2010-03-15 |
Family
ID=37315277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06785258T ATE457979T1 (de) | 2005-06-24 | 2006-06-21 | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7935722B2 (OSRAM) |
| EP (1) | EP1902026B1 (OSRAM) |
| JP (1) | JP5204650B2 (OSRAM) |
| CN (1) | CN101203491A (OSRAM) |
| AT (1) | ATE457979T1 (OSRAM) |
| AU (1) | AU2006262283B2 (OSRAM) |
| BR (1) | BRPI0611705A2 (OSRAM) |
| CA (1) | CA2612723A1 (OSRAM) |
| CY (1) | CY1110014T1 (OSRAM) |
| DE (1) | DE602006012322D1 (OSRAM) |
| DK (1) | DK1902026T3 (OSRAM) |
| ES (1) | ES2339480T3 (OSRAM) |
| MX (1) | MX2007015905A (OSRAM) |
| PL (1) | PL1902026T3 (OSRAM) |
| PT (1) | PT1902026E (OSRAM) |
| SI (1) | SI1902026T1 (OSRAM) |
| WO (1) | WO2007002181A2 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA98777C2 (en) | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| EP2610256B1 (en) | 2007-09-28 | 2016-04-27 | Cyclacel Limited | Pyrimidine derivatives as protein kinase inhibitors |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| MX2010009162A (es) | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
| HRP20120917T1 (hr) * | 2008-05-16 | 2012-12-31 | Eli Lilly & Company | TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA |
| CN101648933B (zh) * | 2009-09-21 | 2011-07-20 | 四川大学 | 3,4-二氢-4-氧-2h-1-苯并吡喃曼尼希碱类化合物、其制备方法和用途 |
| AR078862A1 (es) * | 2009-11-13 | 2011-12-07 | Lilly Co Eli | Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia |
| UA108222C2 (xx) | 2009-12-21 | 2015-04-10 | СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS | |
| MX338831B (es) * | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
| ME02474B (me) | 2010-05-12 | 2017-02-20 | Radius Health Inc | Terapijski režimi |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| EP2621901B1 (en) | 2010-09-28 | 2015-07-29 | Radius Health, Inc | Selective androgen receptor modulators |
| US20140113824A1 (en) | 2011-05-10 | 2014-04-24 | Bayer Intellectual Property Gmbh | Bicyclic (thio)carbonylamidines |
| US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| CN105339368B (zh) | 2013-06-04 | 2017-08-15 | 拜耳制药股份公司 | 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途 |
| CN103694142A (zh) * | 2013-11-28 | 2014-04-02 | 浙江科技学院 | 4-N-Boc-氨基环己酮的制备方法 |
| WO2015124544A1 (de) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine |
| WO2015140199A1 (de) | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| SMT202300072T1 (it) | 2014-03-28 | 2023-05-12 | Univ Duke | Cancro della mammella mediante l'utilizzo di modulatori selettivi del recetiore degli estrogeni |
| EP3227287B1 (de) | 2014-12-02 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| RU2022108295A (ru) | 2016-06-22 | 2022-04-06 | Эллипсес Фарма Лтд | Способы лечения ar+ рака молочной железы |
| CN117417263A (zh) | 2017-01-05 | 2024-01-19 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
| CN109730996B (zh) * | 2017-03-01 | 2021-08-24 | 浙江大学 | 喹啉结构类型雄激素受体拮抗剂及其应用 |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| MX2020012066A (es) | 2018-05-14 | 2021-04-28 | Nuvation Bio Inc | Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares. |
| CN112423844B (zh) | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
| MA54946A (fr) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals Inc | Procédés et composés |
| MX2021013774A (es) | 2019-05-14 | 2021-12-10 | Nuvation Bio Inc | Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares. |
| TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
| AU2022269568A1 (en) | 2021-05-03 | 2023-11-16 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2024229221A1 (en) * | 2023-05-03 | 2024-11-07 | Capulus Therapeutics, Llc | Androgen receptor modulators and methods for their use |
| CN118993985A (zh) * | 2023-05-17 | 2024-11-22 | 中国医学科学院药物研究所 | 一种具有抗肿瘤活性的化合物，其制备方法及制药用途 |
| CN119874601B (zh) * | 2025-01-06 | 2025-10-31 | 山东大学 | 一种3,3-二甲基-1,2,3,4-四氢-9h-咔唑类衍生物及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959309A (en) * | 1968-01-24 | 1976-05-25 | Sterling Drug Inc. | 3-Amido-1,2,3,4-tetrahydrocarbazoles |
| US4988820A (en) | 1986-02-21 | 1991-01-29 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B) indole-sulponamides |
| GB8924392D0 (en) | 1989-10-30 | 1989-12-20 | Bayer Ag | Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides |
| GB9008108D0 (en) | 1990-04-10 | 1990-06-06 | Bayer Ag | Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles |
| DE4027278A1 (de) | 1990-08-29 | 1992-03-05 | Bayer Ag | Heterocyclisch substituierte indolsulfonamide |
| GB9310635D0 (en) | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| AU2002361430B2 (en) * | 2001-12-14 | 2007-09-13 | Zentaris Gmbh | Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR) |
| DE10164564B4 (de) | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
| AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| UA79504C2 (en) * | 2002-11-07 | 2007-06-25 | Organon Nv | Indols for treating diseases associated with androgen receptors |
| EP1648466A1 (en) * | 2003-07-07 | 2006-04-26 | Boehringer Ingelheim International GmbH | Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| EP1824821A2 (en) | 2004-11-23 | 2007-08-29 | PTC Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
-
2006
- 2006-06-21 JP JP2008518350A patent/JP5204650B2/ja not_active Expired - Fee Related
- 2006-06-21 AU AU2006262283A patent/AU2006262283B2/en not_active Ceased
- 2006-06-21 PL PL06785258T patent/PL1902026T3/pl unknown
- 2006-06-21 CN CNA200680022629XA patent/CN101203491A/zh active Pending
- 2006-06-21 EP EP06785258A patent/EP1902026B1/en not_active Not-in-force
- 2006-06-21 DE DE602006012322T patent/DE602006012322D1/de active Active
- 2006-06-21 MX MX2007015905A patent/MX2007015905A/es active IP Right Grant
- 2006-06-21 AT AT06785258T patent/ATE457979T1/de active
- 2006-06-21 PT PT06785258T patent/PT1902026E/pt unknown
- 2006-06-21 CA CA002612723A patent/CA2612723A1/en not_active Abandoned
- 2006-06-21 WO PCT/US2006/024122 patent/WO2007002181A2/en not_active Ceased
- 2006-06-21 ES ES06785258T patent/ES2339480T3/es active Active
- 2006-06-21 BR BRPI0611705A patent/BRPI0611705A2/pt not_active IP Right Cessation
- 2006-06-21 US US11/917,398 patent/US7935722B2/en not_active Expired - Fee Related
- 2006-06-21 SI SI200630646T patent/SI1902026T1/sl unknown
- 2006-06-21 DK DK06785258.2T patent/DK1902026T3/da active
-
2010
- 2010-04-16 CY CY20101100347T patent/CY1110014T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007002181A3 (en) | 2007-03-01 |
| CA2612723A1 (en) | 2007-01-04 |
| CN101203491A (zh) | 2008-06-18 |
| MX2007015905A (es) | 2008-03-06 |
| ES2339480T3 (es) | 2010-05-20 |
| AU2006262283A1 (en) | 2007-01-04 |
| JP5204650B2 (ja) | 2013-06-05 |
| EP1902026A2 (en) | 2008-03-26 |
| SI1902026T1 (sl) | 2010-07-30 |
| DK1902026T3 (da) | 2010-04-26 |
| CY1110014T1 (el) | 2015-01-14 |
| PL1902026T3 (pl) | 2010-07-30 |
| DE602006012322D1 (de) | 2010-04-01 |
| PT1902026E (pt) | 2010-03-17 |
| JP2008546791A (ja) | 2008-12-25 |
| WO2007002181A2 (en) | 2007-01-04 |
| US20100022550A1 (en) | 2010-01-28 |
| US7935722B2 (en) | 2011-05-03 |
| AU2006262283B2 (en) | 2011-10-13 |
| BRPI0611705A2 (pt) | 2016-11-16 |
| EP1902026B1 (en) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE457979T1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| EA200970500A1 (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ | |
| EA201071317A1 (ru) | ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| EA200970913A1 (ru) | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| EA200870448A1 (ru) | Тризамещенные 1,2,4-триазолы | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| IL206611A0 (en) | Novel imidazolinylmethyl aryl sulfonamides | |
| CY1115153T1 (el) | Μεθοδοι για την αγωγη δερματολογικων διαταραχων | |
| EA200802000A1 (ru) | Фармацевтически приемлемые соли и полиморфные формы | |
| ATE522537T1 (de) | (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis | |
| DOP2009000117A (es) | Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos | |
| ITMI20042187A1 (it) | Derivati isossazolici per allievare il dolore neiropatico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1902026 Country of ref document: EP |